@article{10d4b92d2b7847ceb92a7a97a5b5144d,
title = "Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion",
abstract = "Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL-class patients who did and did not receive a TKI in first remission to be compared. ABL-class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).",
keywords = "ABL-class fusion, paediatric acute lymphoblastic leukaemia, prognostic factors, targeted therapy, tyrosine kinase inhibitor",
author = "Moorman, {Anthony V.} and Claire Schwab and Emily Winterman and Jerry Hancock and Anna Castleton and Michelle Cummins and Brenda Gibson and Nick Goulden and Pam Kearns and Beki James and Kirkwood, {Amy A.} and Donna Lancaster and Mabrouk Madi and Andrew McMillan and Jayashree Motwani and Alice Norton and Aengus O{\textquoteright}Marcaigh and Katharine Patrick and Neha Bhatnagar and Amrana Qureshi and Deborah Richardson and Simone Stokley and Gordon Taylor and {van Delft}, {Frederik W.} and John Moppett and Harrison, {Christine J.} and Sujith Samarasinghe and Ajay Vora",
note = "Funding Information: We would like thank all the patients who took part in this study as well as their families. We acknowledge Blood Cancer UK (formerly Bloodwise) for financial support and the member laboratories of the UK Cancer Cytogenetic Group (UKCCG) for providing cytogenetic data and material; in particular Gavin Cuthbert at the Northern Genetics Service (Newcastle upon Tyne Hospitals NHS Trust) for additional genomic analyses. We acknowledge the input of all the scientists and technicians working in the MRD laboratories: Bristol Genetics Laboratory, Southmead Hospital, Bristol; Molecular Biology Laboratory, Royal Hospital for Sick Children, Glasgow; Molecular Haematology Laboratory, Royal London Hospital, London; and the Molecular Genetics Service, Sheffield Children?s Hospital, Sheffield. Primary childhood leukaemia samples used in this study were provided by the Blood Cancer UK Childhood Leukaemia Cell Bank working with the aforementioned MRD laboratories.",
year = "2020",
month = dec,
doi = "10.1111/bjh.17093",
language = "English (US)",
volume = "191",
pages = "844--851",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",
}